Liver Cancer

>

Latest News

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.
Transarterial Chemoembolization Regimen Shows PFS Improvement in HCC

July 16th 2025

Transarterial chemoembolization plus sorafenib did not significantly improve overall survival in advanced hepatocellular carcinoma vs sorafenib alone.

Data from the TALENTACE trial support TACE plus atezolizumab/bevacizumab as an effective option in those with unresectable hepatocellular carcinoma.
PFS Improves With TACE-Based Regimen in Unresectable Liver Cancer

July 13th 2025

HAIC with oxaliplatin and raltitrexed produced a higher response rate vs other systemic therapy agents in patients with advanced hepatocellular carcinoma.
HAIC Regimen Yields Long-Term Survival in Unresectable HCC

July 8th 2025

SIR-Sphere Y-90 resin microspheres are the only approved radioembolization treatments in the US for both HCC and mCRC.
FDA Approves SIR-Sphere Y-90 in HCC

July 7th 2025

Survival benefits were observed across most post-hoc subgroups treated with anlotinib plus penpulimab, particularly among those with high-risk disease features.
Anlotinib/Penpulimab Enhances Survival vs Sorafenib in Unresectable HCC

May 30th 2025

Latest CME Events & Activities